MRK - Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug
2024-01-30 07:13:44 ET
Summary
- Positive results released from phase 1 China study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive solid tumors.
- Trial initiation of phase 1 study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive tumors, expected in Q1 of 2024.
- Additional results from the phase 1 China study, using CRB-701 for the treatment of patients with nectin-4 positive solid tumors, expected at medical meetings throughout 2024.
- Another ADC, known as PADCEV, is expected to generate $5 billion in projected revenues in urothelial carcinoma.
Corbus Pharmaceuticals ( CRBP ) has been able to post positive results, along with its partner CSPC Pharmaceutical Group from a phase 1 dose-escalation study conducted in China, using the drug CRB-701 [SYS6002] for the treatment of patients with urothelial carcinoma and other solid tumors. Despite positive results being achieved in China, there are a few other catalysts left on deck relating to this program, which might allow for the stock price to trade higher in the coming months. The first of which is that it intends to initiate a phase 1 study using CRB-701 for the treatment of patients with urothelial carcinoma and other nectin-4 positive solid tumors in Q1 of 2024. Another catalyst or catalysts would be the release of additional results from this phase 1 study at medical meetings throughout this year. That's because data presented thus far was only of cohort 1 through cohort 6....
Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug